| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | 세포 배양물에서 수득한 액체의 ｐＨ 변화에 의해 프로테아제를 불활성화시키는 방법 | KR1020137004097 | 2011-08-12 | KR1020130105813A | 2013-09-26 | 야코비알렉산더; 암브로지우스도로테; 도베르틴필리네; 에커만크리스티안; 노트헬퍼프란츠 |
| 본 발명은 생물 약제를 정제하는 조작을 개시할 때, 세포 배양 상청액 내의 pH의 반복적 변화에 의해 프로테아제를 불활성화시키는 방법에 관한 것이다. 우선, pH는 pH 3 내지 5, 이어서 pH 7 내지 9로 설정된다.
|
||||||
| 122 | 황화수소 산생 효소 저해제 | KR1020127008514 | 2010-09-01 | KR1020120073265A | 2012-07-04 | 기쿠치사나에; 나리세아츠시; 사쿠라이고지 |
| 황화수소 발생의 억제를 목적으로 하고, 특히, 황화수소 산생 효소 저해제를 제공하는 것을 과제로 한다. 본 발명자들은 예의 연구의 결과, 카테킨류가 황화수소 산생 효소 저해 활성을 갖는 것을 알아내어 본 발명을 완성시켰다. 즉, 본 발명은 카테킨류를 유효 성분으로 하는 황화수소 산생 효소 저해제를 제공한다.
|
||||||
| 123 | 과일과 야채의 유통기한을 연장하기 위한 숙시네이트 탈수소효소 억제제의 용도 | KR1020117019347 | 2010-02-02 | KR1020110118680A | 2011-10-31 | 리크하이코; 라셰즈헬렌; 라부르데뜨질베르; 데이비스피트하워드; 슈티겔도미니크; 드마이어루크; 머슨4세조지홀리; 포우트로리앤; 타포로실바인 |
| 본 발명은 과일과 야채의 유통기한과 저장안정성을 연장하기 위한 숙시네이트 탈수소효소 억제제의 용도, 숙시네이트 탈수소효소 억제제를 과일 또는 야채를 수확하기 전에 작물에 적용하여 과일과 야채의 유통기한을 연장하는 방법 및 숙시네이트 탈수소효소 억제제로 처리된 과일 또는 야채에 관한 것이다. | ||||||
| 124 | 분비성 루시페라아제를 이용하는 생물 발광 검사 | KR1020097015110 | 2007-12-21 | KR1020090113831A | 2009-11-02 | 레우,마르코피터; 댈리,존마이클 |
| Disclosed herein are methods for determining the amount or activity of one or more luciferases and methods for measuring the luminescent signal generated by one or more luciferases in a sample, the methods comprising incubating the sample with a reactive substrate(s) of the luciferase(s) to be analysed and a reducing agent to inactivate a first luciferase, wherein the first luciferase, in its native form, is a secreted luciferase. | ||||||
| 125 | Ｃ-ＦＭＳ 키나제의 저해제 | KR1020087028212 | 2007-04-18 | KR1020090015066A | 2009-02-11 | 아일리그칼알.; 발렌타인쉘리케이.; 첸진솅; 데스자르라이스레니루이스; 미갈라사나쓰케이.; 톰크주크브루스이.; 월마크; 윌슨케네쓰 |
| The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided. | ||||||
| 126 | ＧＳＫ３ 억제제로서 아미노퀴놀론 | KR1020087024866 | 2007-03-13 | KR1020090007561A | 2009-01-19 | 코시오르바,오아나; 리,베이; 짤데닝스,카트린; 후쿠다,야스미찌; 노무라,마사히로; 세또,시게끼; 유모또,가쯔히로; 오까다,교꼬; 나까무라,아야꼬 |
| Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases. | ||||||
| 127 | 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제 | KR1020087025755 | 2007-03-21 | KR1020090007347A | 2009-01-16 | 로우퍼데이빗제이.; 데이비스로버트제이.; 스타모스딘; 아로노브알렉산더; 다이닝거데이빗디.; 그레이주니어로날드; 쉬진왕; 리판; 레드포드브라이언; 파머뤽; 베티엘랜디스캇; 제이콥스딜런; 맥긴티키라 |
| The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders. | ||||||
| 128 | Ｃ-ＦＭＳ 키나제의 저해제 | KR1020087028261 | 2007-04-18 | KR1020090003343A | 2009-01-09 | 일리그카알알.; 발렌타인셸리케이.; 첸진솅; 데스자라이스러네루이스; 미갈라사나스케이.; 월마크; 윌슨케니스 |
| The invention is directed to compounds of Formula (I): wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided. | ||||||
| 129 | 소프트 단백질분해효소 억제자 및 이의 프로-소프트 폼 | KR1020087017430 | 2006-12-15 | KR1020080077024A | 2008-08-20 | 라이,훙-센; 우,웬겐; 바초브친,윌리엄,더블유. |
| The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | ||||||
| 130 | 세린 프로테아제의 억제제 | KR1020087005022 | 2006-08-01 | KR1020080033481A | 2008-04-16 | 라이온스,스티브; 퍼니,로버트,비. |
| This invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R andS isomers wherein the R isomer is greater than 50% of the mixture. | ||||||
| 131 | 세팔로스포린 C를 글루타릴-7-아미노 세팔로스포란산으로 효소 산화시키는 개선된 방법 | KR1019900010913 | 1990-07-18 | KR100163175B1 | 1998-11-16 | 제프리토마스비센지 |
| 내용 없음. | ||||||
| 132 | 誘導体化3−スチリル−セファロスポリン | JP2018130159 | 2018-07-09 | JP2018188454A | 2018-11-29 | サットン, ラリー ディー.; ユ, ソフィア |
| 【課題】β−ラクタム環の開裂により、β−ラクタマーゼを不活性化できる反応性部分を生成するように設計された、広域スペクトルβ−ラクタマーゼ阻害剤の提供。更にこのような阻害を示すβ−ラクタマーゼ阻害剤及びβ−ラクタム抗生物質の製造方法の提供。 【解決手段】下記式の化合物。 式中、R16はH又はC1〜C3アルコキシ、R2はH、C1〜C6アルキル等、R3〜R8はH、ハロゲン、C1〜C6アルキル等、Lは−CH2−等、Zは−O−、−CH2−等、Xは有機又は無機の脱離基、R1は官能化イミン基又はメチレン官能基、nは0又は1〜5の整数を表す。 【選択図】図1 |
||||||
| 133 | 結合抗CD38抗体 | JP2015247967 | 2015-12-18 | JP6425644B2 | 2018-11-21 | イライアス、キャスリーン、アン; ランデス、グレゴリー; シン、シュエーター; コーヴァー、ウーター; ドレイク、アンドリュー、ウォーリング; ハーク−フレンショー、マリー; スネル、ジェルジュ、パル; ブハスカー、ヴィナイ |
| 134 | 採血管、試薬及びそれらを利用した血液性状分析方法 | JP2017000335 | 2017-01-06 | JPWO2017119508A1 | 2018-11-01 | 細川 和也; 和田 朋子; 金子 寿代; 長谷川 喬彬; 永里 朋香 |
| クエン酸ナトリウム含有採血管で採血された血液を用い、該血液にカルシウム、血液凝固第XII因子(FXII)阻害剤およびカリクレイン阻害剤を添加して血液凝固反応を開始させることを特徴とする、血栓形成能または血液凝固能の分析方法が提供される。好ましくは、前記血液にはさらにヘパリン、ヘパラン硫酸および組織因子が添加され、血栓形成能または血液凝固能の分析が行われる。 | ||||||
| 135 | NK/T細胞リンパ腫の検査方法 | JP2014116444 | 2014-06-05 | JP6416508B2 | 2018-10-31 | 竹内 賢吾 |
| 136 | 新規抗PAD4抗体 | JP2017505334 | 2016-03-07 | JP6369922B2 | 2018-08-08 | 佐藤 衛; 山田 道之; 金澤 智; 豊浦 雅義; 庄屋 雄二; 斉藤 憲二; 山崎 ちひろ |
| 137 | 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法 | JP2017198569 | 2017-10-12 | JP2018052938A | 2018-04-05 | アンダーソン,アナリーザ・シビル; ドナルド,ロバート・ジー・ケイ; フリント,マイケル・ジェームズ; ヤンゼン,カトリン・ウーテ; カリヤーン,ナレンダー・ケイ; ミニンニ,テリ・エル; モラン,ジャスティン・キース; ルッペン,マーク・イー; シドゥ,マニンダー・ケイ |
| 【課題】変異体クロストリジウム・ディフィシル毒素Aおよび/または変異体クロストリジウム・ディフィシル毒素Bが含まれる免疫原性組成物の提供。 【解決手段】哺乳類において、クロストリジウム・ディフィシル毒素Aに対する免疫応答を誘導するための、精製しホルムアルデヒドに接触させられたクロストリジウム・ディフィシル毒素Aおよび薬学的に許容可能なキャリヤーを含む組成物の使用であって、ホルムアルデヒドに接触させられたクロストリジウム・ディフィシル毒素Aが、疎水性相互作用クロマトグラフィーによって精製され、ホルムアルデヒドと接触させることによって生産され、0.001から0.01%のホルムアルデヒドをさらに含む、組成物の使用。 【選択図】図25 |
||||||
| 138 | 複素環化合物 | JP2017510027 | 2016-03-29 | JPWO2016158956A1 | 2018-02-22 | 池田 周平; 小池 竜樹; ▲会▼田 淳平; 伏見 真; 楠本 友和; 杉山 英之; 宮▲崎▼ 雅子; 徳原 秀和; 服部 靖志; 鎌田 信 |
| MAGL阻害作用を有し、神経変性疾患(例、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、外傷性脳損傷、緑内障、多発性硬化症など)、不安障害、疼痛(例、炎症性疼痛、癌性疼痛、神経性疼痛など)、てんかん、うつ病などの予防または治療剤として有用であると期待される化合物を提供する。本発明は、式(I):[式中の各記号は明細書に記載の通りである。]で表される化合物またはその塩に関する。 | ||||||
| 139 | 複素環化合物 | JP2014552058 | 2013-12-10 | JP6224004B2 | 2017-11-01 | 小池 竜樹; 梶田 雄一; 吉川 真人; 池田 周平; 木村 英司; 蓮井 智章; 西 俊哉; 福田 広美 |
| 140 | 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット | JP2014520968 | 2013-03-04 | JP6210982B2 | 2017-10-11 | 片岡 理惠; 守屋 奈緒; 佐貫 博美 |
QQ群二维码
意见反馈
意见反馈